Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Devacell Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution shows that the company's pending matters are being reviewed by different technical experts in different units. Such a spread indicates that the company is pursuing multiple technical paths that require specialized review from different segments of the USPTO.
SALVOZA, M FRANCO G is the busiest examiner for this portfolio, with 1 pending office action. This examiner handles half of the company's total pending actions. With 2 distinct art units involved, the prosecution of these 2 actions may be subject to different examination timelines and standards. Practitioners should be prepared for varied feedback across these two matters, as the involvement of 2 distinct examiners and 2 distinct art units reduces the likelihood of a uniform prosecution experience for the company.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| PENNINGTON, KATIE LEIGH | 1 | 29.7% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 13d |
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | SALVOZA, M FRANCO G | 70d |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030956 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | SALVOZA, M FRANCO G | 1672 | §103§112DPOther | Non-Final OA | 70d | Pending | Apr 07, 2023 |
| 18007902 | RECOMBINANT VIRUSES, SURFACE-ENGINEERED DELIVERY SYSTEMS AND RELATED METHODS | PENNINGTON, KATIE LEIGH | 1634 | §102§103§112Other | Non-Final OA | 13d | Pending | Dec 02, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial